Company: SGBAF
Filing Date: 2025-01-17
Form Type: DRS/A
Source: 0000950123-25-000378
Chunk: 325

Company: SES S.A.
Filing Date: 2025-01-17
Form: DRS/A
Chunk 325
---
2023, total borrowings of EUR 66 million were outstanding under the fixed term facility and the company is in compliance with the covenants specified in the facility. Negotiable European Commercial Paper “NEU CP” (formerly French Commercial paper programme) In 2005 SES put in place a EUR 500 million ‘NEU CP’ program in accordance with articles L213-1to L213-4of the French Monetary and Financial Code and article 6 of the order of May 30, 2016 and subsequent amendments. The maximum outstanding amount of ‘NEU CP’ issuable under the program is EUR 500 million or its counter value at the date of issue in any other authorized currency. On April 25, 2023, this program was extended for one further year. As of December 31, 2023 and 2022, no borrowings were outstanding under this program. European Commercial Paper programme In 2012 SES signed the documentation for the inception of a joint EUR 1,000 million guaranteed European commercial paper program of SES S.A. and SES Global Americas Holdings Inc.. Issuances under the program represent senior unsecured obligations of the issuer and any issuance under the program is guaranteed by the non-issuingentity. The program is rated by Moody’s Investors Services and Fitch Ratings and is compliant with the standards set out in the STEP Market Convention. On 9 July 2021, this program was updated and extended. As of December 31, 2023 and 2022, no borrowings were outstanding under this program. IBOR Reform Regulatory authorities have identified and recommended alternative benchmark rates and best practice to support the transition of IBORs to respective alternatives (e.g. SOFR, €STR, SONIA) . These changes have been reviewed and do not have any material impact on the Group’s consolidated financial statements and future funding capabilities. Note 26—Provisions

| € million   |     | 2023 |    |     | 2022 |    |
| Non-current |     |      |  3 |     |      |  7 |
| Current     |     |      | 88 |     |      | 67 |
| Total       |     |      | 91 |     |      | 74 |

F-81

Confidential Treatment Requested by SES Pursuant to 17 C.F.R. Section 200.83 Consolidated financial statements as of and for the years ended December 31, 2023